Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06519097 · ClinicalTrials.gov registry record · Phase 2
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
A Phase 2 study of IPMN, Pancreatic and Neoplasm of Pancreas, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 2
- Study locations
NCT06519097 is a Phase 2 study of IPMN, Pancreatic and Neoplasm of Pancreas that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 4 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06519097, a Phase 2 study of IPMN, Pancreatic and Neoplasm of Pancreas, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Vitamin E Delta Tocotrienol
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06519097
The ClinicalTrials.gov registry entry for NCT06519097 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with IPMN, Pancreatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06519097 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06519097 about?
NCT06519097 is a clinical study titled "Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)". This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
What is the current status of trial NCT06519097?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-07-09. Estimated completion is 2026-09.
What conditions does trial NCT06519097 study?
This clinical trial studies the following conditions: IPMN, Pancreatic, Neoplasm of Pancreas.
What interventions are being tested in trial NCT06519097?
The interventions under investigation include: Placebo (OTHER), Vitamin E Delta Tocotrienol (DRUG).
Who is sponsoring clinical trial NCT06519097?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06519097 being conducted?
This trial has 2 study locations across Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IPMN, Pancreatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.